Get started
LeMaitre Vascular, Inc.LeMaitre Vascular, Inc.LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

LMAT trade ideas

LeMaitre Vascular (LMAT:NASDAQ) Favourable Long-TermConsolidations Present Investment Entry Opportunity LeMaitre Vascular's stock demonstrates promising prospects for investors seeking long-term gains, especially considering recent consolidations in the market that have created an appealing entry point. Strong Q2 Performance and Anticipated Continued Value Generation The company recently reported record-breaking quarterly sales during Q2, indicating robust operational performance. This positive trajectory is expected to persist, with LeMaitre Vascular positioned to continually enhance value for its shareholders over the long term. Strategic Initiatives Driving Economic Profitability and Positive Investor Sentiment LeMaitre Vascular's strategic initiatives, including significant investments in sales team expansion and the ongoing growth of its asset base, are pivotal contributors to its sustained economic profitability. These efforts also contribute to fostering a positive sentiment among investors, further underlining the company's potential. Investment Outlook: Reiteration of Buy Recommendation with a Target Price of $85 Summing up the analysis, reiterating a buy recommendation for LeMaitre Vascular's stock appears warranted. The company's strategic actions, recent sales milestones, and growth projections align favourably with a positive investment outlook. With these factors in mind, a target price objective of $85 is within sight, reinforcing the potential for significant growth in the stock's value. This content is provided for general information purposes only and is not to be taken as investment advice nor as a recommendation for any security, investment strategy or investment account.
NASDAQ:LMAT
by CapitalMarketsEliteGroup
$LMAT can rise in the next daysContextual immersion trading strategy idea. LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $33,45; stop-loss — $32,46. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:LMATLong
by KozakHlib
Beats estimatesSales grew 9% to $28.4 million. That was well ahead of the $25.9 million that analysts had projected. Operating income surged 14% to $7.2 million. Net income grew 41% to $6 million, or $0.30 per share. That figure blew past the $0.20 that Wall Street was expecting. The board of directors approved a 21% increase to the quarterly dividend and gave the thumbs-up to repurchasing $10 million shares of common stock. Zooming out to the full year, here's how the company performed in 2018: Revenue jumped 5% to $105.6 million. That was solidly ahead of the $103 million that was expected. Net income grew 34% to $22.9 million. However, the bulk of the increase is attributable to one-time gains on business divestitures and acquisitions. EPS jumped 31% to $1.13. This was comfortably above the $1.04 that market watchers were expecting. finance.yahoo.com
NASDAQ:LMAT
by AlenCiken